Presentation Guide for Life Science Companies

Posted April 20, 2018 by OCP | Post a Comment

David H. Crean, PhD, Managing Director and head of our Life Sciences and Healthcare Practice Group provides his thoughts and guidance to entrepreneurs, founders and business owners in the life sciences sector on what he has seen as successful pitches to investors and strategic companies in the initial pitches of their company and technology. By providing as much of the information noted below during the process, we believe that you can improve the probability and chances of landing a transaction that supports company growth or exit strategies. David has also previously authored related articles on this topic that can be viewed here and here. Happy to clarify any topic if needed.


life science

Bio Buck$ Fast Forward: A Start-up’s Guide to Investment Banks

Posted November 05, 2017 by David Crean | Post a Comment

Objective Capital’s David H. Crean to Serve as Guest Panelist at LaunchBio Event, November 14, 2017

San Diego, November 9, 2017 — Objective Capital Partners, a middle market M&A Advisory Firm located in Southern California, is pleased to announce that David H. Crean, Ph.D., one of its Managing Directors who heads its thriving life science and healthcare practice, has been invited to speak as a guest panelist at LaunchBio Series Event for life science companies entitled BIO Buck$ Fast Forward: A Start-ups Guide to Investment Banks. Dr. Crean will be joined by Charlie Adams, Cantor Fitzgerald and Tony Grover, VP of Business Development at Banyan Biomarker.


Capital Financing, m&A, BioBucks, David H. Crean, Entrepreneurs, LaunchBio, Partnering, Start-ups, Investment banking, life science, Uncategorized

Objective Capital Partners Adds CardioCell to Expanding Portfolio of Life Science Companies

Posted September 07, 2016 by admin | Post a Comment

Following Positive Results in Phase IIa Heart Failure Clinical Trial,

CardioCell Chooses Objective Capital to Help Manage Rapid Growth

SAN DIEGO – Sept. 7, 2016 – Objective Capital Partners, a leading middle market investment bank and mergers and acquisition (M&A) advisory firm focused on transactions for companies with enterprise values up to $500 million, is pleased to announce that it has recently been retained by CardioCell LLC to help manage its growth needs. CardioCell, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, recently announced positive data from its Phase IIa clinical trial “Safety and Efficacy of Intravenous Infusion of Ischemia-Tolerant Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Cardiomyopathy” at the European Society of Cardiology (ESC) Congress and is currently planning a Phase III study in early 2017.


m&A, Business Consulting, Cardiovascular, mergers and acquisitions, Capital Fund Raising, Investment banking, life science, San Diego

Featured in Mergers & Acquisitions Magazine

Posted October 20, 2015 by admin | Post a Comment

Objective Capital Partners grows by adding a Life Science Investment Banking practice lead by Dr. David Crean PhD.  Featured in Mergers & Acquisitions Magazine online edition.  


m&A, mergers & Acquisitions, objective capital partners, Investment banking, life science, Uncategorized

This article is provided for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC makes no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person.

Our Services

Learn about our services and how we can help you sell your business successfully.


Contact Us

San Diego Office:
3636 Nobel Dr., Suite 160
San Diego, CA 92122

Los Angeles Office:
10100 Santa Monica Blvd., Suite 300
Los Angeles, CA 90067

Trever Acers
Managing Director
858.663.8662 telephone

Channing Hamlet
Managing Director
858.342.4939 telephone

David H. Crean, Ph.D.
Managing Director
858.461.9490 telephone

Jack J. Florio
Managing Director
858.864.4339 telephone